The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Michael R. Savona
No relevant relationships to disclose
Ian W. Flinn
Research Funding - Novartis; Novartis
Stuart Goldberg
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Robert Leon Robles
Research Funding - Bay Area Cancer Research Institute
David Rizzieri
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Jerald P. Radich
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Michael J. Mauro
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Solveig Ericson
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sandy Yi
No relevant relationships to disclose
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Deciphera; Novartis; Pfizer